Cargando…

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma

BACKGROUND: Axl plays multiple roles in tumourigenesis in several cancers. Here we evaluated the expression and biological function of Axl in renal cell carcinoma (RCC). METHODS: Axl expression was analysed in a tissue microarray of 174 RCC samples by immunostaining and a panel of 11 normal tumour p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, H, Liu, R, Ma, B, Li, X, Yen, H-y, Zhou, Y, Krasnoperov, V, Xia, Z, Zhang, X, Bove, A M, Buscarini, M, Parekh, D, Gill, I S, Liao, Q, Tretiakova, M, Quinn, D, Zhao, J, Gill, P S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647683/ https://www.ncbi.nlm.nih.gov/pubmed/26180925 http://dx.doi.org/10.1038/bjc.2015.237

Ejemplares similares

Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours
por: Green, J, et al.
Publicado: (2006)

The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome
por: Kumar, S R, et al.
Publicado: (2007)

Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer
por: Sun, S, et al.
Publicado: (2015)

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2017)

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
por: Chang, Q, et al.
Publicado: (2008)

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma
por: Bilim, V, et al.
Publicado: (2009)

The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence
por: Sun, C K, et al.
Publicado: (2007)

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
por: Dantas-Barbosa, Carmela, et al.
Publicado: (2017)

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
por: Konings, I R H M, et al.
Publicado: (2010)

Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours
por: Beloueche-Babari, M, et al.
Publicado: (2015)

Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas
por: Farace, P, et al.
Publicado: (2009)

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
por: Mahalingam, D, et al.
Publicado: (2011)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
por: Morgillo, F, et al.
Publicado: (2011)

Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation
por: Boykin, C, et al.
Publicado: (2011)

Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore
por: Zhang, H, et al.
Publicado: (2009)

The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy
por: Yu, Y, et al.
Publicado: (2014)

BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
por: Lin, W-H, et al.
Publicado: (2012)

Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer
por: Li, Meng, et al.
Publicado: (2017)

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation
por: Loriot, Y, et al.
Publicado: (2010)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion
por: Ma, P C, et al.
Publicado: (2007)

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
por: Liu, Y J, et al.
Publicado: (2014)

Selective inhibition of TNF-α-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib
por: Ueno, Y, et al.
Publicado: (2005)

Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells
por: Yang, Q, et al.
Publicado: (2014)

Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer
por: Wang, X, et al.
Publicado: (2014)

miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer
por: Shen, Y, et al.
Publicado: (2013)

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
por: Kususda, Y, et al.
Publicado: (2012)

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer
por: Xiang, R, et al.
Publicado: (2011)

Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase 1/2
por: Yeung, B H Y, et al.
Publicado: (2008)

Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells
por: Kikuchi, J, et al.
Publicado: (2008)

Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy
por: Harada, H, et al.
Publicado: (2009)

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
por: Wang, Y, et al.
Publicado: (2011)

Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells
por: Fung, M K L, et al.
Publicado: (2006)

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
por: Wang, X, et al.
Publicado: (2013)

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib
por: Courtin, Aurelie, et al.
Publicado: (2016)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Expression of PPARδ in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology
por: Takayama, O, et al.
Publicado: (2006)

Downregulated NM23-H1 expression is associated with intracranial invasion of nasopharyngeal carcinoma
por: Liu, S J, et al.
Publicado: (2008)

Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy
por: Tan, Q, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5ic8qtbklk6mtfpfg0ktqh8cva